Claims

1. A formulation for healing neurological disorders, said formulation comprising, along with physiologically acceptable carriers, the following ingredients:

   i) *Arnica montana*

   ii) *Hypericum perforatum*

   iii) *Causticum;*

   iv) *Hyoscyamus niger*;

   v) *Zincum phosphoricum*

   vi) *Natrium muriaticum*;

   vii) *Calcarea phosphorica*

   viii) *Kalium phosphoricum*; and

   ix) *Ferrum phosphoricum*

wherein each ingredient has a potency ranging from tincture to all X, C and LM potencies, preferably ranging from 30 C to about 1 M and the proportion of each ingredient ranges from about 1:1 to about 1:10 with respect to other.

2. The formulation as claimed in claim 1, wherein said physiologically acceptable carriers are selected from a group consisting of whey, sucrose, calcium carbonate, microcrystalline cellulose, carbon, carnauba wax, croscarmellose sodium, stearic acid, magnesium stearate, silicon dioxide and ethanol.

3. The formulation as claimed in claim 1, wherein each ingredient is potentized and is in a form selected from the group consisting of tincture, ethanolic solution and aqueous extract.

4. The formulation as claimed in claim 1, wherein said neurological disorders are selected from the group consisting of Cerebral Palsy—

spastic, hyptonic, athetoid, ataxic; Mental Subnormality; Depression arising from neurological disorders; Autism; Down Syndrome; Global Delays; Developmental Disabilities; Neuropathies; Brain Injuries; Neurometabolic Disorders; Stroke; Attention deficit disorder (ADD); Attention deficit hyperactivity disorder (ADHD); Apert's Syndrome; Congenital Brain Anomalies like Schizencephaly, Pachygyria, Porencephaly; Dystonias; Herido-Familial Mental Retardation; Infantile Hemiplegia; Kernicterus; Learning Disabilities; Multi-Infarct Dementias; Microcephaly; Metabolic Disorders with Neurological Complications; Post Meningo-Encephalitic Brain Damage; Rubinstein Taybi Syndrome; Retts Syndrome; Post Surgical Neurodeficit; Multiple Sclerosis; Subacute sclerosing panencephalitis (SSPE) and various Syndromes and conditions of developmental delay and neurological conditions like Leigh's Encephalopathy, Cornelia De Lange Syndrome, Japanese Encephalitis, Tuberous Sclerosis, Leukodystrophy, Chromosomal Anamolies, Agenesis of Corpus Callosum, and Spinocerebellar Syndrome.

CLAIMS

1) A use of an oral formulation in the preparation of a medicament for treating a neurological disorder in a patient in need thereof, wherein the formulation comprises at least the following ingredients:

a. *Arnica montana;*
b. *Hypericum perforatum;*
c. *Causticum;*
d. *Hyoscyamus niger;*
e. *Zincum phosphoricum;*
f. *Natrium muriaticum;*
g. *Calcarea phosphorica;*
h. *Kalium phosphoricum; and*
i. *Ferrum phosphoricum*

wherein each ingredient has a potency ranging from tincture to all X, C and LM potencies and the proportion of each ingredient ranges from 1:1 to 1:10 with respect to other.

2) The use of claim 1, wherein said ingredients in said formulation have a potency ranging from 30 C to 1 M.

3) The use of claim 1 or claim 2, wherein at least one of the ingredients is potentized and is in the form selected from a group consisting of:
tincture, ethanolic solution and aqueous extract.

4) The use of any one of claims 1 to 3, wherein said medicament is potentized by serial dilution and succusion as a post-formulation step.

5) The use of any one of claims 1 to 4, wherein each of said ingredients is potentized by serial dilution and succusion prior to formulation.

6) The use of any one of claims 1 to 5, wherein the medicament further comprises physiologically acceptable carriers selected from a group consisting of whey, sucrose, calcium carbonate, microcrystalline cellulose, carbon, carnauba wax, croscarmellose sodium, stearic acid, magnesium stearate, silicon dioxide and ethanol.

7) The use of any one of claims 1 to 6, wherein the medicament is formulated for administration in a form selected from the group consisting of tablets, capsules, powders, globules, lozenges, pills, pellets, solution, syrup, elixir, suspension and emulsion.

8) The use of any one of claims 1 to 7 wherein the neurological disorder is selected from the group consisting of: Cerebral Palsy, Mental Subnormality, Autism; Down Syndrome, Global Delays, Developmental Disabilities; Neuropathies, Brain Injuries; Neurometabolic Disorders; Stroke; Attention deficit hyperactivity disorder, Infantile Hemiplegia, Microcephaly and Post Meningo Encephalitic Brain Damage.